A mitochondrial surveillance mechanism activated by SRSF2 mutations in hematologic malignancies.

Autophagy Hematology Leukemias Mitochondria Oncology

Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
07 May 2024
Historique:
medline: 7 5 2024
pubmed: 7 5 2024
entrez: 7 5 2024
Statut: aheadofprint

Résumé

Splicing factor mutations are common in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but how they alter cellular functions is unclear. We show that the pathogenic SRSF2P95H/+ mutation disrupts the splicing of mitochondrial mRNAs, impairs mitochondrial complex I function, and robustly increases mitophagy. We also identified a mitochondrial surveillance mechanism by which mitochondrial dysfunction modifies splicing of the mitophagy activator PINK1 to remove a poison intron, increasing the stability and abundance of PINK1 mRNA and protein. SRSF2P95H-induced mitochondrial dysfunction increased PINK1 expression through this mechanism, which is essential for survival of SRSF2P95H/+ cells. Inhibition of splicing with a glycogen synthase kinase 3 inhibitor promoted retention of the poison intron, impairing mitophagy and activating apoptosis in SRSF2P95H/+ cells. These data reveal a homeostatic mechanism for sensing mitochondrial stress through PINK1 splicing and identify increased mitophagy as a disease marker and a therapeutic vulnerability in SRSF2P95H mutant MDS and AML.

Identifiants

pubmed: 38713535
pii: 175619
doi: 10.1172/JCI175619
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Xiaolei Liu (X)

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, United States of America.

Sudhish A Devadiga (SA)

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, United States of America.

Robert F Stanley (RF)

Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, United States of America.

Ryan M Morrow (RM)

Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, United States of America.

Kevin A Janssen (KA)

Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, United States of America.

Mathieu Quesnel-Vallières (M)

Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States of America.

Oz Pomp (O)

Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, United States of America.

Adam A Moverley (AA)

Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, United States of America.

Chenchen Li (C)

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, United States of America.

Nicolas Skuli (N)

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, United States of America.

Martin P Carroll (MP)

Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, United States of America.

Jian Huang (J)

Coriell Institute for Medical Research, Coriell Institute for Medical Research, Camden, United States of America.

Douglas C Wallace (DC)

Center for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia, Philadelphia, United States of America.

Kristen W Lynch (KW)

Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, United States of America.

Omar Abdel-Wahab (O)

Department of Biochemistry and Biophysics, Memorial Sloan-Kettering Cancer Center, New York, United States of America.

Peter S Klein (PS)

Division of Hematology-Oncology, Univeristy of Pennsylvania, Philadelphia, United States of America.

Classifications MeSH